Overactive Bladder Category Switch Prospects Questioned By Indevus

Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call

More from Archive

More from Pink Sheet